TY - JOUR T1 - Visceral fat and bevacizumab in metastatic colorectal cancer JF - Gut JO - Gut SP - 1449 LP - 1450 DO - 10.1136/gut.2010.213777 VL - 59 IS - 10 AU - A M Jubb Y1 - 2010/10/01 UR - http://gut.bmj.com/content/59/10/1449.abstract N2 - The addition of bevacizumab (a monoclonal antibody against vascular endothelial growth factor, VEGF) to 5-fluorouracil-based chemotherapy has a proven overall survival benefit in metastatic colorectal cancer. Nevertheless, the cost of antibody therapies and increasing evidence that the efficacy of targeted agents may be predicted by patient and tumour characteristics have prompted the investigation of biomarkers that may predict benefit from bevacizumab. Guiu et al examined the impact of body mass index, visceral fat area and subcutaneous fat area on the clinical outcome of patients with metastatic colorectal cancer treated with chemotherapy alone or chemotherapy plus bevacizumab. … ER -